MichaelEdwardDeverMD

Research • Windermere, FL

Principal Investigator, Clinical Research

Join to view full profile

Dr. Dever is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Dever's full profile

Already have an account?

Office
3226 Downs Cove Road
Windermere, FL 34786
Phone+1 407-222-8370

Fax+1 407-214-5543
Is this information wrong?

Summary

Dr. Michael Dever is a researcher in Orlando, FL and is affiliated with multiple hospitals in the area, including Orlando Regional Medical Center and Health Central Hospital. He received his medical degree from University of Kentucky College of Medicine and has been in practice 35 years. He is experienced in travel and tropical medicine, clinical research, and insurance medicine.

Education & Training

TriHealth (Good Samaritan Hospital)Residency, Internal Medicine, 1986
Aultman Hospital/NEOMEDResidency, Anesthesiology, 1984 - 1984
TriHealth (Good Samaritan Hospital)Internship, Internal Medicine, 1982 - 1983
University of Kentucky College of MedicineClass of 1982

Certifications & Licensure

FL State Medical License 1985 - 2026
OH State Medical License 1985 - 1988
American Board of Internal Medicine Internal Medicine
American Academy of Insurance MedicineInsurance Medicine
National Board of Physicians and SurgeonsDiplomate of Internal Medicine

Clinical Trials

12-Week Study of Plecanatide for CIC (The National CIC3 Study) Start of enrollment: 2014 Apr 01
Completed
Phase 3
Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease Start of enrollment: 2018 Aug 27
Completed
Phase 2
A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain Start of enrollment: 2019 May 23
Terminated
Phase 3
Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia Start of enrollment: 2017 Jul 10
Terminated
Phase 2
A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI) Start of enrollment: 2019 Oct 17
Completed
Phase 3
Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I) Start of enrollment: 2019 Dec 30
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

154 citations
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.
Edson D Moreira Jr, Nicholas Kitchin, Xia Xu, Samuel S Dychter, Stephen Lockhart, Alejandra Gurtman, John L Perez, Cristiano Zerbini, Michael E Dever, Timothy W Jennin...> ;The New England Journal of Medicine. 2022 May 19
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.
Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, Harper WL, Duncanson DM, McArthur MA, Florescu DF, McClelland RS, Garcia-Fragoso V, Riesenber...> ;The New England journal of medicine. 2021-12-15
187 citations
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 tr...
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,...> ;Lancet. 2021 Nov 13
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, Barnett ED, Muñoz FM, Maldonado Y, Pahud BA, Domachowske JB, Simões EAF, Sarwar UN, Kitchin N, Cu...> ;The New England journal of medicine. 2021-11-09
809 citations
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.
Stephen J. Thomas, Edson D. Moreira, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen Lockhart, John L. Perez, Gonzalo Pérez Marc, Fernando P. Polack, Cris...> ;The New England Journal of Medicine. 2021 Sep 15
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.
Frenck RW, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, Perez JL, Walter EB, Senders S, Bailey R, Swanson KA, Ma H, Xu X, Koury K, Kalina WV, Cooper D, Jenni...> ;The New England journal of medicine. 2021-05-27
5206 citations
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P Polack, Stephen J Thomas, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen Lockhart, John L Perez, Gonzalo Pérez Marc, Edson D Moreira, Cristian...> ;The New England Journal of Medicine. 2020 Dec 31
Join now to see all

Journal Articles

Serum Troponin I Assessments in 5- to 30-Year-OldsAfter BNT162b2 Vaccination
Timothy E. Albertson . Caitlin Hansen . Smiti Bihari .Juleen Gayed . Xia Xu . J. Abraham Simo´ n-Campos . Michael E. Dever .Jose F. Cardona . Essack Mitha . Jeffrey B...., Infectious disease and therapy, 1/19/2024